magnolol has been researched along with Fatty Liver in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Feng, H; Han, L; Li, Z; Liu, G; Lv, H; Shen, B; Tian, Y; Wu, L; Zhang, Q | 1 |
Cho, IJ; Jang, EJ; Jegal, KH; Jung, JY; Kang, SH; Kim, SC; Kim, YW; Ku, SK; Lee, JH; Lee, JR; Moon, SY; Park, SJ; Zhao, RJ | 1 |
2 other study(ies) available for magnolol and Fatty Liver
Article | Year |
---|---|
Magnolol Alleviates Inflammatory Responses and Lipid Accumulation by AMP-Activated Protein Kinase-Dependent Peroxisome Proliferator-Activated Receptor α Activation.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Biphenyl Compounds; Fatty Liver; Hep G2 Cells; Humans; Hyperlipidemias; Lignans; Lipid Metabolism; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; Oleic Acid; PPAR alpha | 2018 |
Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cell Line; Diet, High-Fat; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fatty Liver; Hepatocytes; Humans; Lignans; Lipogenesis; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Orphan Nuclear Receptors; Signal Transduction; Sterol Regulatory Element Binding Protein 1 | 2015 |